Status: Recruiting
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Affiliated Hospital to Academy of Military Medical SciencesUpdated: Jul 1, 2024Locations: 1
Eligibility criteria
Consistent with the diagnosis of AML [+6]
Serious dysfunction of vital organs(heart, liver or kidney) [+9]